Fibroblast growth factor-10

Abstract

Disclosed is a human FGF-10 polypeptide and DNA (RNA) encoding such FGF-10 polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Such polypeptides may be combined with a suitable pharmaceutical carrier or diluent to provide diagnostic, therapeutic and/or prophylactic effects against various diseases. There is also disclosed methods of utilizing antibodies and antagonists against such polypeptide for therapeutic purposes.

What is claimed is:  
     
         1 . An isolated polynucleotide encoding for FGF-10, said polynucleotide selected from the group consisting of 
 (a) a polynucleotide encoding for the FGF-10 polypeptide having the deduced amino acid sequence of FIG. 1 or a fragment, analog or derivative of said polypeptide;    (b) a polynucleotide encoding for the FGF-10 polypeptide having the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. ______ or a fragment, analog or derivative of said polypeptide.    
     
     
         2 . The polynucleotide of  claim 1  wherein the polynucleotide is DNA.  
     
     
         3 . The polynucleotide of  claim 1  wherein the polynucleotide is RNA.  
     
     
         4 . The polynucleotide of  claim 1  wherein the polynucleotide is genomic DNA.  
     
     
         5 . The polynucleotide of  claim 2  wherein said polynucleotide encodes for FGF-10 having the deduced amino acid sequence of FIG. 1.  
     
     
         6 . The polynucleotide of  claim 2  wherein said polynucleotide encodes for the FGF-10 polypeptide encoded by the cDNA of ATCC Deposit No. ______.  
     
     
         7 . The polynucleotide of  claim 1  having the coding sequence for FGF-10 as shown in FIG. 1.  
     
     
         8 . The polynucleotide of  claim 2  having the coding sequence for FGF-10 deposited as ATCC Deposit No. ______.  
     
     
         9 . A vector containing the DNA of  claim 2 .  
     
     
         10 . A host cell genetically engineered with the vector of  claim 9 .  
     
     
         11 . A process for producing a polypeptide comprising: expressing from the host cell of  claim 10  the polypeptide encoded by said DNA.  
     
     
         12 . A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of  claim 9 .  
     
     
         13 . An isolated DNA hybridizable to the DNA of  claim 2  and encoding a polypeptide having FGF-10 activity.  
     
     
         14 . A polypeptide selected from the group consisting of (i) a FGF-10 polypeptide having the deduced amino acid sequence of FIG. 1 and fragments, analogs and derivatives thereof and (ii) a FGF-10 polypeptide encoded by the cDNA of ATCC Deposit No. ______ and fragments, analogs and derivatives of said polypeptide.  
     
     
         15 . The polypeptide of  claim 14  wherein the polypeptide is FGF-10 having the deduced amino acid sequence of FIG. 1.  
     
     
         16 . An antibody against the polypeptide of  claim 14 .  
     
     
         17 . An antagonist/inhibitor against the polypeptide of  claim 14 .  
     
     
         18 . A method for the treatment of a patient having need of FGF-10 comprising: administering to the patient a therapeutically effective amount of the polypeptide of  claim 14 .  
     
     
         19 . A method for the treatment of a patient having need to inhibit FGF-10 comprising: administering to the patient a therapeutically effective amount of an antagonist/inhibitor against the polypeptide of  claim 14 .  
     
     
         20 . A pharmaceutical composition comprising the polypeptide of  claim 14  and a pharmaceutically acceptable carrier.